lufotrelvir

lufotrelvir is the phosphate prodrug of PF-00835231

Also Known As:

((3S)-3-((2S)-2-((4-methoxy-1H-indol-2-yl)formamido)-4-methylpentanamido)-2-oxo-4-((3S)-2-oxopyrrolidin-3-yl)butoxy)phosphonic acid; (14C)-PF-07304814; 14C labeled PF-07304814; 14C-PF-07304814; 4-methoxy-N-((2S)-4-methyl-1-oxo-1-(((2S)-3-oxo-1-((3S)-2-oxopyrrolidin-3-yl)-4-(phosphonooxy)butan-2-yl)amino)pentan-2-yl)-1H-indole-2-carboxamide; C14-PF-07304814; N-((1S)-1-((((1S)-3-hydroxy-2-oxo-1-(((3S)-2-oxopyrrolidin-3-yl)methyl)propyl)amino)carbonyl)-3-methylbutyl)-4-methoxy-1H-indole-2-carboxamide; PF-00835231; PF-07304814; PF-835231

Networked: 10 relevant articles (3 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Anderson, Annaliesa S: 2 articles (02/2021 - 02/2021)
2.	Binder, Joseph: 2 articles (02/2021 - 02/2021)
3.	Desvignes, Ludovic: 2 articles (02/2021 - 02/2021)
4.	Devlin, Joseph C: 2 articles (02/2021 - 02/2021)
5.	Dittmann, Meike: 2 articles (02/2021 - 02/2021)
6.	Herrera, Alberto: 2 articles (02/2021 - 02/2021)
7.	Ivanova, Ellie: 2 articles (02/2021 - 02/2021)
8.	Koralov, Sergei B: 2 articles (02/2021 - 02/2021)
9.	Loose, Paige: 2 articles (02/2021 - 02/2021)
10.	Mohamed, Adil S: 2 articles (02/2021 - 02/2021)

Related Diseases

1.	COVID-19 12/01/2022 - "Further studies exploring lufotrelvir efficacy in patients with coronavirus disease 2019 are ongoing." 01/01/2022 - "In this review, we focus on the preclinical data of PF-07304814 and its active metabolite derivatives to hopefully provide knowledge for researchers to study SARS-CoV-2 infection." 10/01/2023 - "The overall metabolism of lufotrelvir was determined in human healthy volunteers and clinical trial participants with COVID-19. " 10/01/2023 - "The main circulating metabolite was a hydrolysis product (M7) that was present at concentrations greater than PF-00835231, and this was consistent between healthy volunteers and participants with COVID-19. " 08/03/2023 - "PF-07304814 is a covalent inhibitor targeting SARS-CoV-2 Mpro with favorable inhibition potency and drug-like properties, thus making it a promising drug candidate for the treatment of COVID-19. "
2.	Infections 01/01/2022 - "PF-00835231 can inhibit not only cell infection (such as Vero E6, 293T, Huh-7.5, HeLa+angiotensin-converting enzyme 2 (ACE2), A549+ACE2, and MRC-5) but also the human respiratory epithelial organ model and animal model infection. "

Related Drugs and Biologics

1.	Antiviral Agents (Antivirals)
2.	plitidepsin (aplidine)
3.	nirmatrelvir
4.	AT-511
5.	molnupiravir
6.	lufotrelvir
7.	Prodrugs
8.	Phosphates (Orthophosphate)
9.	Protease Inhibitors (Protease Inhibitor)
10.	Peptide Hydrolases (Proteases)

Related Therapies and Procedures

1.	Therapeutics
2.	Intravenous Infusions